By Cameron Hannum, Pharm.D., Senior Clinical Account Pharmacist, Enlyte
Generic versions of Nucynta are now available in the U.S. market. For workers’ compensation claims, this may create brand-to-generic conversion opportunities, especially as part of a longer-term pain regimen.
What Changed
In March 2026, Hikma Pharmaceuticals PLC launched generic versions of Nucynta ER (extended-release tapentadol), following their February 2026 release of generic Nucynta IR (immediate-release tapentadol). The introduction of these generics offers adjusters a significant cost-saving opportunity while continuing to maintain effective pain management options.
What to Look for in Your Claims
Tapentadol may appear on claims involving acute injury-related pain, ongoing severe pain or mixed pain conditions. This medication (a centrally-acting synthetic analgesic) is available in two formulations.
- Nucynta IR (Immediate-Release): Indicated for the treatment of acute pain severe enough to require an opioid pain medication when other treatments are not effective enough.
- Nucynta ER (Extended-Release): Indicated for managing severe, ongoing pain in adults that require around-the-clock opioid treatment when other pain treatments do not provide adequate relief, including immediate-release opioids. It is also indicated for treating ongoing nerve pain from diabetic peripheral neuropathy (DPN) in adults when other treatments are not sufficient.
How Tapentadol Can Reduce Claim Cost
These generics represent a significant development in accessibility and affordability. Authorized generics typically launch at 10-25% below brand pricing, with potential for greater discounts over time. Given this, the availability of generic tapentadol could generate substantial savings, particularly for long-term therapy cases. A pharmacy benefit manager (PBM) can help you target brand-to-generic conversion opportunities for these claim saving opportunities.
Why It Matters on a Claim
Tapentadol is a commonly prescribed opioid worldwide and its dual mechanism makes it useful in treating acute, chronic and nerve pain in injured employees.
It offers a unique advantage in pain management by addressing both traditional pain pathways and neuropathic pain components. This dual action makes it particularly valuable for injured employees with mixed pain conditions—where both tissue damage (nociceptive pain) and nerve involvement (neuropathic pain) are present.
For example, adjusters might see work injury conditions like low back pain with radiculopathy (nerve compression of the spine) or DPN (widespread nerve damage). Injured employees often experience both these types of pain simultaneously. With tapentadol, one component helps address the burning, tingling or electrical sensations characteristic of nerve pain, while the opioid component addresses the more traditional aching or throbbing pain.
What Safety Issues Should Adjusters Consider
Tapentadol’s dual mechanism can create important safety considerations, particularly when used with certain medications, including alongside Serotonergic medications such as:
- Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine (Prozac) or sertraline (Zoloft)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like duloxetine (Cymbalta) or venlafaxine (Effexor XR)
- Tricyclic antidepressants like amitriptyline or nortriptyline
- MAO inhibitors like selegiline or isocarboxazid
- Certain migraine medications such as triptans including sumatriptan or rizatriptan
- Some antibiotics like linezolid
The combination of tapentadol with these medications can increase the risk of serotonin syndrome—a potentially life-threatening condition characterized by mental status changes, autonomic instability and neuromuscular and gastrointestinal symptoms. In severe cases, serotonin syndrome can lead to seizures, loss of consciousness and even death if not promptly treated.
For adjusters and case managers reviewing these medications, it’s important to ensure prescribers are aware of all the medications the injured employee is taking, particularly antidepressants or other pain medications that might affect serotonin or norepinephrine levels. Your pharmacy benefit manager can also help you identify any concerning drug interactions.
Evidence-Based Alternatives
Tapentadol is one option for pain management, but it is not the only one. When evaluating tapentadol therapy adjusters should also consider the following alternatives:
Non-Opioid Options:
- Oral or topical NSAIDs
- Acetaminophen
- Anticonvulsants such as gabapentin or pregabalin
- Antidepressants such as duloxetine or amitriptyline
- Over-the-counter topical agents such as lidocaine or capsaicin
Opioid Alternatives:
- Traditional opioids such as morphine, oxycodone or hydrocodone
- Tramadol which offers lower potency but a similar dual mechanism
- Buprenorphine
Non-pharmacological care can also help support recovery and reduce reliance on medication. Depending on the claim, this can include physical therapy to improve function, cognitive behavioral therapy to address pain-related coping challenges, interventional procedures for targeted pain relief and complementary therapies such as acupuncture or massage. For adjusters, these options may be worth considering when pain persists, function stalls or medication risk starts to outweigh the benefit.
The Bottom Line
The arrival of generic Nucynta IR and Nucynta ER offer new cost-effective pain management options but also raise questions regarding safety concerns. When adjusters know what to look for, they are in a better position to flag concerns early, support safer pharmacy management and make more informed decisions. PBMs like ScriptAdvisor® can also help identify conversion opportunities and medication risks when additional review is needed.
About the Author
Cameron is a senior clinical pharmacist for Enlyte Pharmacy Solutions. In his role, he serves in a client-facing capacity as part of the pharmacy benefit Management (PBM) team and is responsible for supporting and partnering with insurers, third-party administrators and direct employers in developing and operationalizing strategic pharmacy initiatives for their clinical programs.
Cameron is also a regular contributor to the Ask the Pharmacist Series where this article originally appeared.
www.enlyte.com/ask-the-pharmacist
